4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1-methylimidazole | 489447-43-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1-methylimidazole
• CAS: 489447-43-0
• 化学式: C₁₆H₁₁Cl₃N₂
• 分子量: 337.636
• InChiKey: ZYWBSHNWUZEQMU-UHFFFAOYSA-N

物化性质

• 沸点：
  466.2±40.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异氰酸己酯 、 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1-methylimidazole 生成 N-(hexyl)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1-methylimidazole-2-carboxamide
  参考文献：
  名称：

  Substituted imidazoles as cannabinoid receptor modulators

  摘要：

  本发明涉及使用本发明的化合物作为大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，特别是用于治疗、预防和抑制由大麻素-1（CB1）受体介导的疾病。本发明涉及使用这些新型化合物选择性拮抗大麻素-1（CB1）受体。因此，本发明的化合物在治疗精神病、记忆障碍、认知障碍、偏头痛、神经病理、神经炎症性疾病（包括多发性硬化症和吉兰-巴雷综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病和精神分裂症方面是有用的。这些化合物还可用于治疗物质滥用障碍，特别是对阿片类、酒精和尼古丁的治疗。这些化合物还可用于治疗与过度食物摄入和相关并发症相关的肥胖症或进食障碍。本发明还声明了结构式（I）的新型化合物。

  公开号：

  US20060089356A1
• 作为产物：
  描述：

  碘甲烷 、 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)imidazole 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1-methylimidazole 、 5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-imidazole
  参考文献：
  名称：

  Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

  摘要：

  Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CBI receptor inverse agonists resulted in the discovery of the two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4.0 nM) which also demonstrated efficacy in overnight feeding studies in the rat for reduction in both food intake and overall body weight. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.078

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP2026798A1

  公开（公告）日：2009-02-25
• US7057051B2
  申请人：——

  公开号：US7057051B2

  公开（公告）日：2006-06-06
• US7572785B2
  申请人：——

  公开号：US7572785B2

  公开（公告）日：2009-08-11
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES CONTENANT DES MODULATEURS DE RÉCEPTEURS AUX CANNABINOÏDES CBX ET DES MODULATEURS DE CANAUX POTASSIUM
  申请人：SOLVAY PHARM GMBH

  公开号：WO2007125048A1

  公开（公告）日：2007-11-08

  [EN] The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one K_ATP channel modulator as a first active agent and b) at least one CB_x modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.
  [FR] L'invention concerne des compostions pharmaceutiques contenant des quantités pharmaceutiquement efficaces a) d'au moins un modulateur de canal K_ATP servant de premier agent actif et b) d'au moins un modulateur de CB_x servant de deuxième agent actif. L'invention concerne également l'utilisation de telles compositions et des procédés de traitement, de prévention, de retardement de la progression, de retardement du déclenchement et/ou d'inhibition d'une pluralité de troubles tels que l'obésité, le diabète sucré, le syndrome métabolique, le syndrome X, l'insulinome, l'hypoglycémie hyperinsulémique familiale, l'alopécie androgénétique, l'hyperréactivité du détrusor, l'asthme, la neuroprotection, l'épilepsie, l'analgésie, la cardioprotection, l'angine de poitrine, la cardioplégie, l'arythmie, les spasmes coronariens, les maladies vasculaires périphériques, les vasospasmes cérébraux, la régulation de l'appétit, la neurodégénération, les douleurs telles que les douleurs neuropathiques et chroniques, et l'impuissance chez l'homme et les mammifères, par administration de telles compositions à des sujets nécessitant un tel traitement. L'invention concerne également des procédés de fabrication de telles compositions.
• Substituted imidazoles as cannabinoid receptor modulators
  申请人：——

  公开号：US20030114495A1

  公开（公告）日：2003-06-19

  The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

  本发明涉及将这些新型化合物用于选择性拮抗Cannabinoid-1（CB1）受体。因此，本发明的化合物可用作治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（包括多发性硬化症和吉兰-巴雷综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病和精神分裂症的精神药物。这些化合物还可用于治疗物质滥用障碍，特别是阿片类药物、酒精和尼古丁。这些化合物还可用于治疗与过度食物摄入及相关并发症相关的肥胖或进食障碍。同时还声明了结构式（I）的新型化合物。